CCL4 and central nervous system cancer: These results imply that serum CCL4 levels may act as a non-invasive biomarker to differentiate between gliomas and inflammatory conditions, providing a valuable resource for enhancing diagnostic precision and potentially minimizing the necessity for invasive diagnostic methods in clinical settings.